Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY98-7443 (LNG + Indomethacin) IUS vs Jaydess for Contraception
NCT03562624Phase 2Completed
- Sponsor
- Bayer
- Start
- Jun 2018
- Primary completion
- May 2019
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of BAY 987443 in contraception (4 arms), sponsored by Bayer. Primary endpoint: Number of uterine bleeding/spotting (B/S) days at 90 days. Started Jun 2018; status: completed.
02
Drugs
BAY 987443
03
Conditions
contraception
Beyond the preview
Go deeper on NCT03562624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562624.